Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders

Author(s): Rahul Maheshwari, Muktika Tekade, Piyoosh A. Sharma, Rakesh Kumar Tekade

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 30 , 2015

Become EABM
Become Reviewer


Cardiovascular diseases (CVDs), primarily myocardial infarction (MI), atherosclerosis, hypertension and congestive heart failure symbolize the foremost cause of death in almost all parts of the world. Besides the traditional therapeutic approaches for the management of CVDs, newer innovative strategies are also emerging on the horizon. Recently, gene silencing via small interfering RNA (siRNA) is one of the hot topics amongst various strategies involved in the management of CVDs. The siRNA mechanism involves natural catalytic processes to silence pathological genes that are overexpressed in a particular disease. Also the versatility of gene expression by siRNA deciphers a prospective tactic to down-regulate diseases associated gene, protein or receptor existing on a specific disease target. This article reviews the application of siRNA against CVDs with special emphasis on gene targets in combination with delivery systems such as cationic hydrogels, polyplexes, peptides, liposomes and dendrimers.

Keywords: Cardiovascular disorders, myocardial infarction, RNAi, siRNA.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [4427 - 4440]
Pages: 14
DOI: 10.2174/138161282130151007150300
Price: $65

Article Metrics

PDF: 43